Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.


AIMS The aim of this study was to investigate the relationship between the use of bevacizumab (Bmab) in addition to oxaliplatin (OX), the development of sinusoidal obstruction syndrome (SOS) and the changes in splenic volume as an indicator of the protective effect of Bmab against OX-induced SOS. METHODS Seventy-nine patients who received OX-based… (More)
DOI: 10.1016/j.ejso.2013.12.009


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics